Table 5 Univariate distribution of lifestyle/medication exposures and key comorbidities by sexual dysfunction domains among men with chronic hepatitis C.

From: Sexual dysfunction among Egyptian men with chronic hepatitis C in the post elimination era prevalence and associated factors

Variable

Premature ejaculation

(N = 1002)

n (%)

Erectile dysfunction

(N = 931)

n (%)

Desire dysfunction

(N = 849)

n (%)

Tea consumption:

Yes

No

924 (92.2%)

78 (7.8%)

858 (92.2%)

73 (7.8%)

782 (92.1%)

67 (7.9%)

P value

0.762

0.922

0.946

Tramadol intake,

Yes

No

47 (4.7%)

955 (95.3%)

37 (4.0%)

894 (96.0%)

25 (2.9%)

824 (97.1%)

P value

< 0.001**

< 0.001**

< 0.001**

Beta-blocker use

Yes

No

149 (14.9%)

853 (85.1%)

137 (14.7%)

794 (85.3%)

98 (11.5%)

751 (88.5%)

P value

< 0.001**

< 0.001**

0.725

Spironolactone use

Yes

No

782 (78.0%)

220 (22.0%)

782 (84.0%)

149 (16.0%)

770 (90.7%)

79 (9.3%)

P value

< 0.001**

< 0.001**

< 0.001**

Diabetes mellitus (DM)

Yes

No

155 (15.5%)

847 (84.5%)

145 (15.6%)

786 (84.4%)

117 (13.8%)

732 (86.2%)

P value

< 0.001**

< 0.001**

< 0.001**

Hepatocellular carcinoma (HCC)

Yes

No

84 (8.4%)

918 (91.6%)

83 (8.9%)

848 (91.1%)

81 (9.5%)

768 (90.5%)

P value

< 0.001**

< 0.001**

< 0.001**

  1. Denominators (N) are provided in column headers. Values are n (%); percentages are per column. P values compare exposure (Yes/No) across each outcome column using χ² (or Fisher’s exact when expected counts < 5). Two-sided p < 0.05.; Significant at p  < 0.05, ** highly Significant.
Back to article page